FDA Accepts Supplemental NDA for Diacomit (Stiripentol) by Biocodex
The FDA has accepted a supplemental NDA for Diacomit, an epilepsy treatment containing stiripentol.
Asset / Drug
Drug and asset intelligence for Biocodex with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.